Evaluation of bioequivalence of two products containing 400 mg ibuprofen and 100 mg caffeine: Ibuprofen / Caffeine 400 mg / 100 mg coated granules (Test) vs. Thomapyrin TENSION DUO, 400mg / 100mg Filmtabletten (Reference). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

2023-509752-34-00 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 7 Sep 2024 · End 23 Sep 2024 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 28
Countries 1
Sites 1

No therapeutic indication in the current trial with healthy volunteers.

Key facts

Sponsor
CCDRD Cooperative Clinical Drug Research and Development AG, Hermes Pharma GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
7 Sep 2024 → 23 Sep 2024
Decision date (initial)
2024-08-09
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

No therapeutic indication in the current trial with healthy volunteers.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

CCDRD Cooperative Clinical Drug Research and Development AG

Sponsor organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Address
Lindenallee 70, Dahlwitz-Hoppegarten Dahlwitz-Hoppegarten
City
Hoppegarten
Postcode
15366
Country
Germany

Scientific contact point

Organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Contact name
Project Manager

Public contact point

Organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Contact name
Project Manager

Hermes Pharma GmbH

Sponsor organisation
Hermes Pharma GmbH
Address
Georg-Kalb-Strasse 5, Grosshesselohe, Großhesselohe Grosshesselohe Großhesselohe
City
Pullach I. Isartal
Postcode
82049
Country
Germany

Scientific contact point

Organisation
Hermes Pharma GmbH
Contact name
Manager Medical Science & Regulatory Service

Public contact point

Organisation
Hermes Pharma GmbH
Contact name
Manager Medical Science & Regulatory Service

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 28 1
Rest of world 0

Investigational sites

Bulgaria

1 site · Ended
Clinic of Clinical Pharmacology and Therapeutics UMHAT Tsaritsa Ioanna-ISUL' EAD
Clinic of Clinical Pharmacology and Therapeutics, 'Bialo more' Str. 8, Bulgaria, Sofia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2024-09-07 2024-09-23 2024-09-07 2024-09-08

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-15 Bulgaria Acceptable
2024-08-05
2024-08-09